LINC01016 enhances the malignant phenotype of endometrial cancer cells, impacting their growth and survival with key molecular pathways involved.
The study identifies the relation between LINC01016 and two microRNAs: miR-302a-3p and miR-3130-3p, with potential implications for targeted therapy.
Assessment using molecular pathway analysis demonstrates how LINC01016 regulates NFYA and SATB1 within cancer cells, supporting the hypothesis of a regulatory axis.
These findings suggest that targeting LINC01016 may enable new therapeutic approaches for endometrial cancer; additional research is warranted.